These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. De Meerleer G; Fonteyne V; Meersschout S; Van den Broecke C; Villeirs G; Lumen N; Ost P; Vandecasteele K; De Neve W Radiother Oncol; 2008 Nov; 89(2):205-13. PubMed ID: 18771809 [TBL] [Abstract][Full Text] [Related]
6. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980 [TBL] [Abstract][Full Text] [Related]
7. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. King CR; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668 [TBL] [Abstract][Full Text] [Related]
8. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204 [TBL] [Abstract][Full Text] [Related]
9. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. King CR; Presti JC; Brooks JD; Gill H; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902 [TBL] [Abstract][Full Text] [Related]
10. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity. Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582 [TBL] [Abstract][Full Text] [Related]
11. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452 [TBL] [Abstract][Full Text] [Related]
12. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785 [TBL] [Abstract][Full Text] [Related]
13. Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients. Jereczek-Fossa BA; Vavassori A; Fodor C; Santoro L; Zerini D; Cattani F; Garibaldi C; Cambria R; Fodor A; Boboc GI; Vitolo V; Ivaldi GB; Musi G; de Cobelli O; Orecchia R Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):784-94. PubMed ID: 18191332 [TBL] [Abstract][Full Text] [Related]
14. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586 [TBL] [Abstract][Full Text] [Related]
15. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456 [TBL] [Abstract][Full Text] [Related]
16. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959 [TBL] [Abstract][Full Text] [Related]
17. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549 [TBL] [Abstract][Full Text] [Related]
18. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539 [TBL] [Abstract][Full Text] [Related]
19. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014 [TBL] [Abstract][Full Text] [Related]
20. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]